BioPoint Inc

04/24/2026

Regeneron won FDA approval for a groundbreaking gene therapy for rare genetic hearing loss, marking a major milestone in genetic medicine.

The therapy signals a new era by targeting the root genetic cause of disease rather than just symptoms. https://www.fiercepharma.com/pharma/regeneron-ushers-new-genetic-medicine-era-groundbreaking-gene-therapy-approval

Travis Smith was a very serious baby. Born completely unable to hear, his mother Sierra struggled to see his personality shine through his mute world. | Travis Smith was a very serious baby. Born completely unable to hear, his mother Sierra struggled to see his personality shine through his mute wor...

04/23/2026

Roche says its amylin-based obesity drug still has value due to fewer side effects compared to GLP-1 therapies. The company is positioning it as an option for patients who prioritize tolerability over maximum weight loss. https://www.biospace.com/business/roche-insists-amylin-obesity-drug-still-valuable-for-patients-who-dont-want-side-effects

Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.

04/22/2026

Ionis’ antisense drug showed stabilization in patients with an ultra-rare neurological disease ahead of an upcoming U.S. Food and Drug Administration decision. The results support its potential as the first disease-modifying treatment if approved. https://www.biospace.com/drug-development/ionis-antisense-drug-stabilizes-ultra-rare-disease-ahead-of-fda-decision

The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and overall data.

04/21/2026

At AACR 2026, companies like Moderna, Revolution Medicines, Zymeworks, and BeOne presented new cancer data highlighting advances in targeted therapies and immuno-oncology. The updates underscore growing momentum in next-generation treatments, particularly those targeting difficult cancers like RAS-driven tumors. https://www.biospace.com/drug-development/aacr-2026-moderna-revolution-zymeworks-and-beone-showcase-new-data

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

04/21/2026

Novo Nordisk reported strong late-stage results for its sickle cell drug, showing meaningful improvements in pain crises and hemoglobin levels. The success raises the competitive bar, putting increased pressure on rival drugmakers. https://www.biospace.com/drug-development/novos-late-stage-sickle-cell-win-piles-pressure-on-competitors

Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.

04/16/2026

A fantastic evening at La Padrona following Day 1 of the .

Thank you to everyone who joined BioPoint for our post-summit mixer. It’s always energizing to step outside the sessions and into meaningful conversations with leaders across biotech and life sciences—where ideas are exchanged, challenges are shared, and real connections are made.

These moments matter. They’re where collaboration begins, perspectives shift, and the future of our industry quietly takes shape.

We’re grateful to be part of a community that continues to push innovation forward—and even more grateful for the people behind it.

04/16/2026

Eli Lilly reported strong diabetes data for Foundayo, reinforcing its safety profile. The results may help ease recent FDA concerns around potential risks. https://www.biospace.com/business/lillys-foundayo-posts-outstanding-diabetes-data-possibly-easing-fda-safety-concerns

Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the indication.

04/15/2026

The U.S. Food and Drug Administration has flagged safety concerns with Eli Lilly’s new obesity pill and is requesting additional data. The concerns include potential risks like liver issues and other side effects, despite the drug’s recent approval. https://www.biospace.com/fda/lillys-new-obesity-pill-linked-to-serious-safety-signals-fda-requests-more-data

The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.

04/14/2026

Johnson & Johnson reported strong Q1 results and is targeting over $100 billion in revenue for 2026. Growth is being driven by oncology and immunology drugs, helping offset losses from key patent expirations. https://www.biospace.com/business/with-nearly-a-quarter-billion-in-q1-j-j-targets-100b-revenue-in-2026

With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.

04/13/2026

Are you at the ? Come listen this afternoon as Jay Destino talks about how outsourcing partners can benefit your projects.

04/09/2026

BioSpace’s 2026 IPO tracker follows biotech companies going public as the market begins to reopen after a slow period. Early activity suggests cautious optimism, with larger IPOs signaling renewed investor confidence. https://www.biospace.com/business/ipo-tracker-2026

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.

04/08/2026

Fierce Pharma’s 2026 regulatory tracker highlights ongoing drug approvals and label expansions across global markets, tracking how therapies gain new uses and reach more patients. It shows steady regulatory momentum, with companies expanding existing drugs into new indications and regions to drive growth. https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but...